SLC5A2 and type 2 diabetes mellitus: Patients with T2DM and cardiac hypertrophy, diastolic or systolic dysfunction or with a hypervolemic state (regardless of cardiac or renal origin) are the best candidates for treatment with SGLT2 inhibitors [114].